拔管后经鼻高流量氧疗与持续气道正压通气对危重患儿呼吸支持解除时间的影响:一项随机临床试验
这项在22个儿科重症监护病房开展的实用性、多中心、随机、非劣效性试验纳入600名0至15岁拔管后72小时内需无创呼吸支持的危重患儿,1:1随机接受经鼻高流量氧疗(HFNC,n=299)或持续气道正压通气(CPAP,7-8 cm H2O,n=301)。主要终点为随机化至呼吸支持解除的时间,非劣效界值为校正风险比(HR)0.75。HFNC未能达到非劣效标准,中位解除时间50.5小时(95%CI 43.0-67.9) vs CPAP 42.9小时(95%CI 30.5-48.2),校正HR 0.83(单侧97.5%CI 0.70-∞)。6项预设次要终点中5项无显著差异,包括48小时内再插管率(HFNC 13.3% vs CPAP 11.5%);第180天死亡率HFNC显著更高(5.6% vs 2.4%;校正OR 3.07 [95%CI 1.1-8.8])。
要点
- 在22个儿科ICU的600名拔管后需无创呼吸支持的危重患儿中,HFNC未能达到非劣效于CPAP的标准(校正HR 0.83;单侧97.5%CI 0.70-∞,非劣效界值0.75)。
- 呼吸支持解除中位时间HFNC 50.5小时(95%CI 43.0-67.9) vs CPAP 42.9小时(95%CI 30.5-48.2)。
- 第180天死亡率HFNC显著高于CPAP(5.6% vs 2.4%;校正OR 3.07 [95%CI 1.1-8.8])。
- 48小时内再插管率HFNC 13.3% vs CPAP 11.5%,无显著差异。
- 最常见不良事件为腹胀(HFNC 8/281 [2.8%] vs CPAP 7/272 [2.6%])和鼻/面部损伤(HFNC 14/281 [5.0%] vs CPAP 15/272 [5.5%])。
适用人群与场景
- 0至15岁危重患儿,拔管后72小时内经临床评估需无创呼吸支持者,纳入英国22个儿科重症监护病房。
诊断标准与关键阈值
- 主要终点呼吸支持解除定义为开始连续48小时无任何形式呼吸支持(有创或无创)的时段起点。
- 非劣效界值为校正风险比(HR)0.75。
处置流程与药物剂量
- HFNC组按患者体重设定流量开始治疗(n=299)。
- CPAP组以7至8 cm H2O开始治疗(n=301)。
研究设计与关键结果
- 实用性、多中心、随机、非劣效性试验,22个儿科重症监护病房,2019年8月8日至2020年5月18日招募600名患儿,末次随访2020年11月22日完成。
- 主要分析纳入553名患儿(HFNC 281;CPAP 272;中位年龄3个月;241名女孩[44%])。
- HFNC未能达到非劣效标准:中位呼吸支持解除时间50.5小时(95%CI 43.0-67.9) vs CPAP 42.9小时(95%CI 30.5-48.2);校正HR 0.83(单侧97.5%CI 0.70-∞)。
- 预设亚组结果相似。
- 6项预设次要终点中5项无显著差异,包括48小时内再插管率(HFNC 13.3% vs CPAP 11.5%)。
- 第180天死亡率HFNC显著更高(5.6% vs CPAP 2.4%;校正OR 3.07 [95%CI 1.1-8.8])。
- 最常见不良事件为腹胀(HFNC 8/281 [2.8%] vs CPAP 7/272 [2.6%])和鼻/面部损伤(HFNC 14/281 [5.0%] vs CPAP 15/272 [5.5%])。
证据类型、等级与局限
- 随机、多中心、非劣效性临床试验(ISRCTN60048867)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在拔管后需要无创呼吸支持的危重患儿中,与CPAP相比,HFNC未能达到呼吸支持解除时间的非劣效标准。
指南或共识出处
- JAMA发表的随机临床试验(ISRCTN60048867)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The optimal first-line mode of noninvasive respiratory support following extubation of critically ill children is not known.
OBJECTIVE: To evaluate the noninferiority of high-flow nasal cannula (HFNC) therapy as the first-line mode of noninvasive respiratory support following extubation, compared with continuous positive airway pressure (CPAP), on time to liberation from respiratory support.
DESIGN, SETTING, AND PARTICIPANTS: This was a pragmatic, multicenter, randomized, noninferiority trial conducted at 22 pediatric intensive care units in the United Kingdom. Six hundred children aged 0 to 15 years clinically assessed to require noninvasive respiratory support within 72 hours of extubation were recruited between August 8, 2019, and May 18, 2020, with last follow-up completed on November 22, 2020.
INTERVENTIONS: Patients were randomized 1:1 to start either HFNC at a flow rate based on patient weight (n = 299) or CPAP of 7 to 8 cm H2O (n = 301).
MAIN OUTCOMES AND MEASURES: The primary outcome was time from randomization to liberation from respiratory support, defined as the start of a 48-hour period during which the child was free from all forms of respiratory support (invasive or noninvasive), assessed against a noninferiority margin of an adjusted hazard ratio (HR) of 0.75. There were 6 secondary outcomes, including mortality at day 180 and reintubation within 48 hours.
RESULTS: Of the 600 children who were randomized, 553 children (HFNC, 281; CPAP, 272) were included in the primary analysis (median age, 3 months; 241 girls [44%]). HFNC failed to meet noninferiority, with a median time to liberation of 50.5 hours (95% CI, 43.0-67.9) vs 42.9 hours (95% CI, 30.5-48.2) for CPAP (adjusted HR, 0.83; 1-sided 97.5% CI, 0.70-∞). Similar results were seen across prespecified subgroups. Of the 6 prespecified secondary outcomes, 5 showed no significant difference, including the rate of reintubation within 48 hours (13.3% for HFNC vs 11.5 % for CPAP). Mortality at day 180 was significantly higher for HFNC (5.6% vs 2.4% for CPAP; adjusted odds ratio, 3.07 [95% CI, 1.1-8.8]). The most common adverse events were abdominal distension (HFNC: 8/281 [2.8%] vs CPAP: 7/272 [2.6%]) and nasal/facial trauma (HFNC: 14/281 [5.0%] vs CPAP: 15/272 [5.5%]).
CONCLUSIONS AND RELEVANCE: Among critically ill children requiring noninvasive respiratory support following extubation, HFNC compared with CPAP following extubation failed to meet the criterion for noninferiority for time to liberation from respiratory support.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN60048867.
参考来源
- Ramnarayan P, Richards-Belle A, Drikite L, et al. Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Following Extubation on Liberation From Respiratory Support in Critically Ill Children: A Randomized Clinical Trial. JAMA. 2022. PMID: 35390113. doi:10.1001/jama.2022.3367
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。